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this, we observed that the downstream
effectors of the Wnt pathway, i.e.,
c-myc and Skp2 were not expressed
in KSCs by reverse transcription–PCR
(Figure 1b). Further, probing cell
lysates of WIF1-arrested keratinocytes
in western blots revealed that Wnt3A/
WIF1 treatment resulted in increased
p21 protein levels (Figure 2o) demon-
strable quantitatively (Figure 2p).
Thus, WIF1 may achieve its cell cycle
arrest in keratinocytes at least in
part through derepression of p21
transcription.
In conclusion, we report that WIF1
is, to our knowledge, previously unre-
ported as a marker of interfollicular
KSCs, and that it inhibits cell cycle
progression in human keratinocytes
even in the presence of activating
Wnt signals (Wnt3A). Although cano-
nical Wnt signaling appears to be dis-
pensable during development in the
interfollicular epidermis (Huelsken
et al., 2001; Nguyen et al., 2009), our
data suggest that inhibition of Wnt
signaling may be required for keeping
interfollicular stem cells quiescent and
differentiating cells from proliferating
during homeostasis.
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TO THE EDITOR
Bombesin and two major bombesin-like
peptides in mammals, gastrin-releasing
peptide (GRP) and neuromedin B, have
been shown to elicit various physiological
effects. GRP elicits gastrin release and
regulates gastric acid secretion and motor
function (Merali et al., 1999). This peptide
is also involved in the biology of the
circadian system. Interestingly, intra-
dermal injections of GRP elicit scratch-
ing in mice (Andoh et al., 2011). GRP is
expressed in a subset of peptidergic dorsal
root ganglion neurons, whereas GRP
receptor (GRPR) is expressed in lamina I
of the dorsal spinal cord (Sun and Chen,
2007). When lamina I neurons expressing
GRPR in the spinal cord were selectively
ablated, the mice showed profound
scratching deficits in response to all of
the itching stimuli tested, irrespective of
their histamine dependence (Sun et al.,
2009). These data support the labeled lineAccepted article preview online 25 January 2013
Abbreviations: AD, atopic dermatitis; GRP, gastrin-releasing peptide; GRPR, GRP receptor; PGP, protein
gene product; VAS, visual analog scale
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for itching in the spinal cord and provide
an important cellular basis for explaining
how a pruritogenic stimulus is perceived
by the brain as a major sensation.
Atopic dermatitis (AD) is an inflam-
matory pruritic skin disorder. Mechan-
ical trauma resulting from extensive
scratching that is precipitated by inten-
sive itching results in skin barrier dys-
function and exacerbation of AD
(Barnes, 2010). So far, severe pruritus
in AD has been attributed to increased
release of substance P, nerve growth
factor, neurotrophin-3 and 4, brain-
derived neurotrophic factor, histamine,
and IL-31 (Arck and Paus, 2006; Lee
et al., 2006; Scuri et al., 2010; Lee and
Yu, 2011). It was recently reported that
a proportion of protein gene product
(PGP) 9.5þ nerve fibers expressed GRP
in both the epidermis and the dermis of
NC/Nga mice, the most popular AD
model mice (Tominaga et al., 2009). In
this study, we examined serum GRP
levels in AD and their correlation with
visual analog scale (VAS) itch scores.
A total of 53 AD patients (mean±SD
age: 36.4±12.6 years, 31 men and 22
women) and 35 healthy controls (41.6±
16.0 years, 11 men and 24 women) were
enrolled in this study. All AD patients
were given diagnoses according to the
criteria of Hanifin and Rajka (1980).
We rated itch by VAS 0–10, asking
the patients to mark a point on the
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Figure 1. Serum gastrin-releasing peptide (GRP) levels in atopic dermatitis patients. (a) Serum GRP levels
in 53 atopic dermatitis patients and 35 healthy individuals. Each bar indicates the mean of each group.
(b) Correlations between serum GRP levels and visual anlog scale (VAS) itch scores.
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Figure 2. Double immunofluorescence staining for gastrin-releasing peptide (GRP) and protein gene product (PGP) 9.5. Dermal PGP 9.5þ nerve fibers (red)
expressed GRP (green). Increased numbers of double-positive fibers (yellow) in lesional skin of atopic dermatitis compared with normal skin. Representative two
cases in each group. Bar ¼ 100mm.
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line corresponding to mean itch during
the last 7 days before blood draw. The
medical ethical committee of the Uni-
versity of Tokyo approved all described
studies, and the study was conducted
according to the Declaration of Helsinki
Principles. Informed consent was ob-
tained from participants. The 35 healthy
controls had no history of allergy or
pruritus. Enzyme immunoassay was per-
formed using GRP EIA kit obtained from
Phoenix Pharmaceuticals (Burlingame,
CA). Biopsy specimens obtained from
AD patients (n¼ 5) and healthy controls
(n¼ 6) were snap-frozen, cut into 5-mm-
thick cryostat sections, and fixed in acet-
one. These sections were then stained
with rabbit anti-human GRP antibody
(number H-027-07, Phoenix Pharma-
ceuticals) and mouse anti-human PGP
9.5 mAb (13C4/I3C4, Abcam plc,
Cambridge, UK), followed by corres-
ponding secondary antibodies labeled
with Alexa-Fluor 488 or Alexa-Fluor
594 (Molecular Probes, Eugene, OR).
The numbers of double-positive fibers
per 100 field were counted indepen-
dently by two investigators in a blinded
manner. The w2 goodness-of-fit test was
used to evaluate normality for all para-
meters. The F-test was used to evaluate
the equality of variance between two
groups. Welch’s t test was used for
comparison between two groups. Corre-
lation coefficients were determined by
using Spearman’s rank correlation test.
Po0.05 was considered significant.
Serum GRP levels in AD patients
were significantly higher than in healthy
individuals (3.11±0.98 and 2±
0.58 ng ml1, respectively; Po0.001,
Figure 1a). When serum GRP levels
higher than the meanþ 2 SD of the
control serum samples were considered
to be elevated, the percentage of
elevated samples in AD were 45.2%.
We compared serum GRP levels with
other laboratory data reflecting disease
activity of AD, such as serum levels of
IgE, sIL–2R, IL-31, CCL17, and numbers
of eosinophils in peripheral blood. There
was no significant relation between
serum GRP levels and these markers
(data not shown). By contrast, there was
a significant correlation between serum
GRP levels and VAS itch scores
(r¼0.725, Po0.01, Figure 1b). We next
performed double immunofluorescence
staining for GRP and PGP 9.5. In both
AD lesional skin and normal skin, der-
mal PGP 9.5þ nerve fibers expressed
GRP (Figure 2), as was previously repor-
ted in NC/Nga mice. Absorption experi-
ments suggested that immunoreactivity
in the epidermis was false-positive (data
not shown). The number of GRPþ nerve
fibers in AD skin (5.0±1.2 per 100
field) was significantly larger than
that of normal skin (2.7±0.8 per
100 field).
We clearly demonstrated that serum
GRP levels in AD patients were signifi-
cantly higher than in healthy indivi-
duals, and that they correlated with
VAS itch scores. Transepidermal water
loss and serum levels of b-endorphin
and IgE are useful biomarkers for itch
intensity in AD patients (Lee et al.,
2006). IL-31 is also regarded as a key
cytokine for the development of AD-
induced skin inflammation and pruritus
(Bilsborough et al., 2006). However,
serum IgE and IL-31 levels did not
correlate with VAS itch scores in this
study. Although further studies with a
large number of cases are required,
serum GRP levels could be a better
biomarker of itch in AD patients. No
significant correlation between serum
GRP levels and serum IgE or IL-31
levels in this study has also suggested
multiple pathways for itch sensation.
GRP-induced scratching was inhibited
by the m-opioid receptor antagonist
naltrexone hydrochloride, the GRPR
antagonist RC-3095, the H1 histamine
receptor antagonists fexofenadine
hydrochloride and chlorpheniramine
maleate, and the PAR2 proteinase-
activated receptor antagonist FSLLRY-
NH2 (Andoh et al., 2011). It has
recently been reported that central
GRPR and neuromedin B receptor act
independently to elicit scratching
behavior and that there is an
additional, unidentified receptor
mechanism underlying bombesin-
elicited scratching (Su and Ko, 2011).
In summary, elevated serum GRP levels
and increased numbers of dermal GRPþ
nerve fibers suggested that this peptide
could be a therapeutic target for itch in
AD patients.
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